GMILogo_Vertical-Gradient.png
Carcinoembryonic Antigen Market to hit $2.7bn by 2023: Global Market Insights, Inc.
20 avr. 2017 06h30 HE | Global Market Insights, Inc
Ocean View, Delaware, April 20, 2017 (GLOBE NEWSWIRE) -- The research report “Carcinoembryonic Antigen (CEA) Market Size By Application (Colorectal, Pancreatic, Ovarian, Breast, Thyroid Cancer),...
Recent Publication H
Recent Publication Highlights Proof-of-Concept Data Supporting the Diagnostic Potential of Phosphatidylserine-Positive Exosomes in Ovarian Cancer
09 févr. 2017 08h05 HE | Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high...
VB-111 Clinical Data
VB-111 Clinical Data Presented at ASCO Demonstrate Significant Increase in Overall Survival in Platinum-Resistant Ovarian Cancer
06 juin 2016 07h00 HE | VBL Therapeutics
VB-111 demonstrated a statistically significant increase in overall survival at therapeutic vs. low dose level (810 days vs. 172 days, p=0.042)60% (9 of 15) durable response rate (as measured by...
Carcinoembryonic ant
Carcinoembryonic antigen (CEA) market size worth $2.78 Billion by 2023: Global Market Insights Inc.
16 mai 2016 07h30 HE | Global Market Insights, Inc
Dover, DE, May 16, 2016 (GLOBE NEWSWIRE) -- Carcinoembryonic antigen (CEA) market size is forecast to reach USD 2.78 billion by 2023; as reported in the latest study by Global Market Insights,...